FDA Safety and Innovation Act, Part 1
Senior Food and Drug Administration (FDA) officials gave an update on the implementation of the 2012 FDA Safety and Inno…
| Clip Of FDA Safety and Innovation Act, Part 2
This clip, title, and description were not created by C-SPAN.
Report Video IssueUser Clip: Rep. Engel questions FDA's Dr. Janet Woodcock
2013-11-15T11:42:20-05:00https://images.c-span.org/Files/19a/20131115114426002_hd.jpgMentions rare disease, accelerated approval, Duchenne muscular dystrophy; Sarepta Therapeutics & eteplirsen, patient advocacy, establishing natural history of rare diseases
Mentions rare disease, accelerated approval, Duchenne muscular dystrophy; Sarepta Therapeutics & eteplirsen, patient advocacy, establishing natural history of rare diseases
People in this video
- Eliot Engel U.S. Representative [D] New York
- Janet Woodcock M.D. Director U.S. Food and Drug Administration->Center for Drug Evaluation and Research
Hosting Organization
More Videos From
House Energy & Commerce Committee: Implementation of FDA Safety & Innovation Act
Purchase a Download
User Clip: Rep. Engel questions FDA's Dr. Janet Woodcock
-
MP4 video - Standard
- Price:
- $4.99 or Free with MyC‑SPAN
-
MP3 audio - Standard
- Price:
- $0.99
Related Video
-
-
FDA Transparency and Oversight, Panel on Correcting Misinformation
Physicians and medical researchers talked about ways for the Food and Drug Administration to correct misinformation in t…
-
FDA Transparency and Oversight, Investor Panel
A forum on transparency at the Food and Drug Administration featured a discussion on how transparency can affect investo…
-
Generic Drug Labeling
Witnesses testified at a hearing on the Food and Drug Administration’s FDA’s proposal to have generic drug makers update…
User Created Clips from This Video
-
- 4 minutes
- 304 views
-
- 8 minutes
- 18 views
-
- 1 minute
- 13 views
-
- 23 seconds
- 5 views